We found for
Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
![Understanding the Context Cover Page](https://www.ohe.org/wp-content/uploads/2018/04/Understanding-the-Context-Cover-Page_1.jpg)
Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
![2016](https://www.ohe.org/wp-content/uploads/2017/04/2016.jpg)
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
![NICE CAR T front page](https://www.ohe.org/wp-content/uploads/2017/02/NICE-CAR-T-front-page.jpg)
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
![Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover](https://www.ohe.org/wp-content/uploads/2016/12/MCDA-Front-Cover.jpg)